Minirin Melt (Desmopressin Acetate)

• Desmopressin acetate is employed in disorders where antidiuretic activity or coagulation factor elevation is required.
• Central diabetes insipidus: reduces excessive urine output by enhancing water reabsorption in the kidneys.
• Nocturnal enuresis: decreases nighttime bedwetting by concentrating urine.
• Primary nocturnal polyuria: limits nocturnal urine volume through V2‑receptor activation.
• Hemophilia A: raises plasma factor VIII levels to improve clotting.
• Von Willebrand disease: increases von Willebrand factor, aiding haemostatic control.

• Desmopressin acetate acts as a selective V2‑receptor agonist in the renal collecting ducts, stimulating cyclic AMP formation and promoting insertion of aquaporin‑2 channels, which enhances water reabsorption. The same V2 activation on endothelial cells raises plasma concentrations of factor VIII and von Willebrand factor, providing antidiuretic and haemostatic effects respectively.

Desmopressin acetate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea or abdominal discomfort.
• Nasal congestion or rhinorrhoea.
• Facial flushing or warmth.
• Mild hyponatraemia without symptoms.

Serious or Rare Side Effects

• Severe hyponatraemia leading to seizures or coma.
• Water intoxication with rapid weight gain.
• Allergic reactions such as rash, itching or angioedema.
• Thrombotic events in patients with high factor VIII levels.
• Hypertensive crisis when combined with vasopressin antagonists.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

• Assess serum sodium: check baseline and periodically during treatment.
• Monitor fluid balance: advise patients to limit excessive water intake.
• Caution in renal impairment: adjust dose or increase monitoring frequency.
• Use conservatively in the elderly: increased susceptibility to hyponatraemia.
• Contraindicated in uncontrolled hyponatraemia or severe renal failure.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Desmopressin may interact with other medicines that affect water balance or coagulation.

Major Interactions (Avoid)

• Concomitant use with vasopressin antagonists (e.g., conivaptan) can negate therapeutic effect.
• Loop diuretics may exacerbate hyponatraemia risk.
• Carbamazepine accelerates desmopressin clearance, reducing efficacy.

Moderate Interactions (Monitor Closely)

• NSAIDs can impair renal prostaglandin synthesis, increasing hyponatraemia risk.
• Antihypertensives may potentiate blood pressure changes when fluid shifts occur.
• Estrogen‑containing therapies can enhance V2‑receptor response, requiring sodium monitoring.